A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

✍ Scribed by Cappuzzo, F.; Novello, S.; De Marinis, F.; Selvaggi, G.; Scagliotti, G.V.; Barbieri, F.; Maur, M.; Papi, M.; Pasquini, E.; Bartolini, S.; Marini, L.; Crinò, L.

• Book ID: 119319383
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 167 KB
• Volume: 52
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/j.lungcan.2006.03.004